Estimated Total Annual Burden Hours: 5400.

In compliance with the requirements of Section 3506 (c) (2) (A) of the Paperwork Reduction Act of 1995, the Administration for Children and Families is soliciting public comments on the specific aspects of the information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Planning Research and Evaluation, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. All Requests should be identified by the title of the information collection.

The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

#### Robert Sargis,

Reports Clearance Officer. [FR Doc. 2011–31493 Filed 12–7–11; 8:45 am] BILLING CODE 4184–01–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Administration for Children and Families

President's Committee for People With Intellectual Disabilities Notice of Committee Meeting via Conference Call

**AGENCY:** President's Committee for People with Intellectual Disabilities (PCPID), Administration for Children and Families, HHS.

**ACTION:** Notice of Committee meeting via conference call.

**DATE:** Wednesday, February 1, 2012, from 1 p.m. to 2:30 p.m. EST. This meeting, to be held via audio conference call, is open to the public.

Details for accessing the full Committee Conference Call, for the public, are cited below:

Toll Free Dial-In Number: (888) 989– 0724

Pass Code: 1939592

Individuals who will need accommodations in order to participate in the PCPID Meeting via audio conferencing (assistive listening devices, materials in alternative format such as large print or Braille) should notify Genevieve Swift, PCPID Executive Administrative Assistant, at Edith.Swift@acf.hhs.gov, or by telephone at (202) 619–0634, no later than Wednesday, January 25, 2012. PCPID will attempt to meet requests for accommodations made after that date, but cannot guarantee ability to grant requests received after this deadline.

Agenda: Committee Members will discuss plans for developing the PCPID 2012 Report to the President.

Additional Information: For further information, please contact Laverdia Taylor Roach, Senior Advisor, President's Committee for People with Intellectual Disabilities, The Aerospace Center, Second Floor West, 370 L'Enfant Promenade SW., Washington, DC 20447. Telephone: (202) 619–0634. Fax: (202) 205–9519. Email: LRoach@acf.hhs.gov.

SUPPLEMENTARY INFORMATION: PCPID acts in an advisory capacity to the President and the Secretary of Health and Human Services, through the Administration on Developmental Disabilities, on a broad range of topics relating to programs, services, and supports for persons with intellectual disabilities. The PCPID Executive Order stipulates that the Committee shall: (1) Provide such advice concerning intellectual disabilities as the President or the Secretary of Health and Human Services may request; and (2) provide advice to the President concerning the following for people with intellectual disabilities: (A) expansion of educational opportunities; (B) promotion of homeownership; (C) assurance of workplace integration; (D) improvement of transportation options; (E) expansion of full access to community living; and (F) increasing access to assistive and universally designed technologies.

Dated: December 1, 2011.

## Jamie Kendall,

Deputy Commissioner, Administration on Developmental Disabilities.

[FR Doc. 2011–31539 Filed 12–7–11; 8:45 am]

BILLING CODE 4184-01-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Food and Drug Administration [Docket No. FDA-2010-N-0381]

### Generic Drug User Fee; Public Meeting

**AGENCY:** Food and Drug Administration, HHS

**ACTION:** Notice of public meeting; request for comments.

The Food and Drug Administration (FDA) is announcing a public meeting to discuss proposed recommendations for enactment of a Generic Drug User Fee Act (GDUFA), which will authorize FDA to collect fees and use them for the process for the review of human generic drug applications and associated Type II Active Pharmaceutical Ingredient Drug Master Files (DMFs) and for conducting associated inspections for fiscal years (FYs) 2013–2017. New legislation would be required for FDA to establish and collect user fees under such a program. FDA and the regulated industry have developed a proposal for Congressional consideration. In the interest of transparency, and in an effort to voluntarily follow a process similar to the ones set forth in the Federal Food, Drug, and Cosmetic Act for FDA's other user fee programs, FDA is publishing the negotiated recommendations (the goals letter), holding a meeting at which the public may present its views on such recommendations, and providing an opportunity for the public to provide written comments on such recommendations.

Date and Time: The public meeting will be held on December 19, 2011, from 10 a.m. to 5 p.m. Registration to attend the meeting must be received by December 12, 2011. The meeting will also be Web cast. See Section III. B. of this document for information on how to register for the meeting and Section III.C. on information about how to access the Web cast. Please submit any comments that you plan to present at the public meeting to the docket by the date of the public meeting but note that written or electronic comments must be submitted by January 6, 2011.

ADDRESSES: The meeting will be held at the FDA White Oak Campus, 10903
New Hampshire Ave., Bldg. 2, rm. 2047, Silver Spring, MD 20993. Submit electronic comments to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the